Literature DB >> 21358307

The United States National Health and Nutrition Examination Survey and the epidemiology of ankylosing spondylitis.

Charles F Dillon1, Rosemarie Hirsch.   

Abstract

Currently available U.S. population-based data for ankylosing spondylitis (AS), spondyloarthritis and inflammatory back pain (IBP) from the nationally representative U.S. National Health and Nutrition Examination Survey (NHANES) include both NHANES I (1971-1975) and NHANES II (1976-1980) surveys. The pelvic radiographs obtained in NHANES I provided U.S. prevalence estimates for radiographic sacroiliitis, an important component of the AS case definition. AS and spondyloarthritis prevalences cannot readily be calculated from NHANES I survey data; however, IBP prevalence (Rudwaleit et al Criteria 7b) can be estimated from NHANES II. The NHANES II estimate for IBP is 0.8% of the adult population ages 25 to 49 years. The prevalence of IBP in the subset of persons with a history of a back pain episode lasting 2 or more weeks was 6.7%. The 2009-2010 NHANES U.S. Inflammatory Back Pain/Spondyloarthritis survey is currently fielded.

Entities:  

Mesh:

Year:  2011        PMID: 21358307     DOI: 10.1097/MAJ.0b013e31820f8c83

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  11 in total

1.  Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey.

Authors:  John D Reveille; James P Witter; Michael H Weisman
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-01-24       Impact factor: 4.794

2.  Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting.

Authors:  Jeffrey R Curtis; Leslie R Harrold; Maryam M Asgari; Atul Deodhar; Craig Salman; Joel M Gelfand; Jashin J Wu; Lisa J Herrinton
Journal:  Perm J       Date:  2016-07-29

3.  Prevalence of chronic axial pain, inflammatory back pain, and spondyloarthritis in diagnosed psoriasis.

Authors:  Nicole Thom; Christopher T Ritchlin; Xiao Zhang; John Reveille; Michael H Weisman
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

4.  High frequency of inflammatory back pain and other features of spondyloarthritis in patients with rheumatoid arthritis.

Authors:  Gercek Can; Dilek Solmaz; Omer Binicier; Servet Akar; Merih Birlik; Ozgul Soysal; Nurullah Akkoc; Metin Manisali; Fatos Onen
Journal:  Rheumatol Int       Date:  2012-11-06       Impact factor: 2.631

Review 5.  Inflammatory back pain: the United States perspective.

Authors:  Michael H Weisman
Journal:  Rheum Dis Clin North Am       Date:  2012-08       Impact factor: 2.670

Review 6.  The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States.

Authors:  John D Reveille; Michael H Weisman
Journal:  Am J Med Sci       Date:  2013-06       Impact factor: 2.378

7.  The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009-10.

Authors:  Michael H Weisman; James P Witter; John D Reveille
Journal:  Ann Rheum Dis       Date:  2012-07-11       Impact factor: 19.103

Review 8.  The efficacy of moxibustion and acupuncture therapy for ankylosing spondylitis: A protocol for an overview of systematic reviews and meta-analysis.

Authors:  Qingyuan Zhu; Jun Chen; Jun Xiong; Lunbin Lu; Siyuan Zhu; Zhiying Zhong; Genhua Tang; Xingchen Zhou; Han Guo
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

9.  Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis.

Authors:  Qiang Tong; Qing Cai; Tristan de Mooij; Xia Xu; Shengming Dai; Wenchun Qu; Dongbao Zhao
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

10.  Successful Nonoperative Treatment of a Lumbar Spine Extension Injury with Disruption of all Three Bony Columns in a Patient with Ankylosing Spondylitis - A Case Report.

Authors:  Ali Faqeeh; David Yen
Journal:  Open Neurol J       Date:  2017-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.